Casopitant
- Generic Name
- Casopitant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35F7N4O2
- CAS Number
- 414910-27-3
- Unique Ingredient Identifier
- 3B03KPM27L
- Indication
Investigated for use/treatment in urinary incontinence and adverse effects (chemotherapy).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 710
- Registration Number
- NCT00601172
- Locations
- 🇸🇰
GSK Investigational Site, Poprad, Slovakia
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00511823
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00358813
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 515
- Registration Number
- NCT00334152
- Locations
- 🇹ðŸ‡
GSK Investigational Site, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath